XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2012 Credit Suisse Healthcare Conference. The live presentation will occur at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time) on Wednesday, November 14, 2012. A replay of the presentation will also be available.
To access the live presentation via the Web, please go to
. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and will be available approximately 24 hours after the live presentation.
XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved in the United States for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia in adults. GlaxoSmithKline holds commercialization rights and certain development rights for
in the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved for the treatment of RLS in Japan. Astellas Pharma Inc. holds all development and commercialization rights for
in Japan and five other Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson's disease and relapsing-remitting multiple sclerosis.
To learn more about XenoPort, please visit the Web site at
are registered trademarks of XenoPort, Inc.
is a registered U.S. trademark of GlaxoSmithKline.